Merit of an Ursodeoxycholic Acid Clinical Trial in COVID-19 Patients
Corona Virus Disease 2019 (COVID-19) has affected over 8 million people worldwide. We underscore the potential benefits of conducting a randomized open-label unblinded clinical trial to evaluate the role of ursodeoxycholic acid (UDCA) in the treatment of COVID-19. Some COVID-19 patients are characte...
Guardat en:
| Autors principals: | , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
MDPI AG
2020-06-01
|
| Col·lecció: | Vaccines |
| Matèries: | |
| Accés en línia: | https://www.mdpi.com/2076-393X/8/2/320 |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|